Gallagher et al. reported that blocking CD47 enhanced anti-CD19 antibody-mediated phagocytosis of both lymphoma and normal B cells, suggesting that concomitant CD47 blockade may be used to potentiate B cell depletion therapy [30]. The gene discussed is CD47; the disease is lymphoma.